TFPI

TFPI

TFPI 분자 정보

Molecule Name
Tissue factor pathway inhibitor
분자 별명
TFPI,LACI,TFPI1,EPI,TFI
Drug Development Progress
임상 약물 수3
시판 약물 수2
최고 연구 개발 단계Approved
표적 별명
TFPI,Tissue Factor Pathway Inhibitor,Extrinsic Pathway Inhibitor,TFPI1,LACI,EPI,Anti-Convertin,TFI,Lipoprotein-associated coagulation inhibitor,Tissue Factor Pathway Inhibitor (Lipoprotein-Associated Coagulation Inhibitor)
분자 배경
Tissue factor pathway inhibitor (TFPI) is also known as Extrinsic pathway inhibitor (EPI), Lipoprotein - associated coagulation inhibitor (LACI), is a plasma proteinase inhibitor synthesized by vascular endothelial cells and part of it is associated with glycosaminoglycans of these cells. TFPI is a single-chain polypeptide which can reversibly inhibit Factor Xa (Xa) and Thrombin (Factor IIa). TFPI is a secreted protein with a N­terminal acidic region, three Kunitz (K) domains separated with by two linker regions, and a C­terminal basic region. The first K domain inhibits coagulation factor VIIa complexed to tissue factor (TF); The second K domain inhibits factor Xa; The third K domain binds to heparin; The C­terminal basic region may have several functions. For example, it plays an important role in binding of TFPI to cell surfaces.

TFPI 제품 목록

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
KN-057KN-057; KN057Phase 3 ClinicalSuzhou Alphamab Co Ltd
Hemophilia A; Hemophilia B
상세
MG-1113MG-1113; MG-1113APhase 1 ClinicalGC Biopharma Corp
Hemophilia A
상세
AP-017AP017; AP-017Phase 1 ClinicalAnyuan Pharmaceutical Technology (Shanghai) Co Ltd
Hemophilia A; Hemophilia B
상세

시판 약물 정보

영어 이름연구 코드연구 개발 단계회사가장 빠른 브랜드 이름가장 빠른 승인 국가가장 빠른 적응증가장 빠른 승인 회사가장 빠른 승인 날짜적응증임상 시험
ConcizumabAnti-TFPI; mAb-2021; NNC-0172-2021; NNC-172-2021; mAbTFPI2021; NN-7415; NNC-0172-0000-2021ApprovedNovo Nordisk A/SAlhemoCanadaHemophilia BNovo Nordisk Canada Inc2023-04-17
Hemophilia A; Hemophilia B; Hemorrhage
상세
MarstacimabPF-6741086; PF-06741086ApprovedPfizer IncHYMPAVZI, 友瑞宁United StatesHemophilia A; Hemophilia BPfizer Inc2024-10-11
Hemophilia A; Hemophilia B; Hemorrhage
상세